Depression (Major Depressive Disorder): SSRI Choice, SI Safety Screens & Withdrawal Mimics

Major depressive disorder groups a syndrome of sad or empty mood or marked loss of interest together with cognitive and somatic disturbances that exceed culturally expected grief reactions (see NHS framing of persistence beyond brief low spells). Contemporary models blend monoamine and neurotrophic hypotheses with psychosocial stress circuitry—effective treatment therefore spans psychotherapy, medications that modulate synaptic transmission, and, for severe or resistant illness, neurostimulation or intensive programmes per national guidance such as NICE NG222.

Nurses anchor care by translating those mechanisms into observable function: sleep continuity, nutritional intake, treatment adherence, cardiovascular fitness, and ability to participate in therapy homework. The illness heightens all-cause healthcare utilisation and magnifies suffering in people managing chronic physical diagnoses—pair mood treatment with condition-specific education so patients are not caught between contradictory self-management demands.

DSM-5-TR criteria operationalise episode diagnosis through symptom count, duration, and impairment; clinicians often layer validated questionnaires for severity trending. The PHQ-9 remains ubiquitous in collaborative-care models because it links scores with treatment intensity and tracks response—interpret scores alongside safety, not instead of it.

↔On a small screen, swipe or scroll sideways to see the full table.

Item 9 (passive or active suicidal thoughts) never stands alone—any non-zero response warrants structured risk questioning even if the total score looks “mild.”

Affective symptoms dominate media portrayals, yet wards more often notice sleep fragmentation, early waking, insomnia, appetite collapse or emotional overeating, psychomotor agitation or slowing, guilt rumination, poor concentration, and anxiety tension. Somatic champions—unexplained headache, abdominal distress, chest tightness—may be the only endorsed concerns, especially among people socialised away from naming sadness.

Populations that skew atypical

• Older adults: “depression without sadness” with apathy, weight loss, or failure-to-thrive prompts overlap with dementia and delirium—time of onset and attentional fluctuations help triage.
• Peripartum individuals: rapid onset mood lability, insomnia despite infant sleep, or intrusive guilt may signal postpartum depression needing obstetric-liaison pathways.
• Substance-associated contexts: alcohol or sedative withdrawal, stimulant crash, and chronic alcohol use disorder mime depression until substances stabilise.

Risk accumulates across genetic loading, early adversity, chronic medical burden, and recent losses. WHO emphasises interacting social, psychological, and biological factors; CDC mental-health materials likewise stress chronic disease bidirectionality. Modifiable contributors include harmful alcohol use, sleep debt, social isolation, and untreated pain—targets for collaborative planning even when antidepressants are indicated.

Modifiable vs contextual

• Modifiable: substance misuse patterns, occupational burnout, IPV exposure recovery plans, glycaemic chaos in type 2 diabetes mellitus, sedentary physiology.
• Structural / less modifiable: family history, developmental trauma history, personality disorder traits complicating alliance, neurodevelopmental conditions affecting emotional regulation.

Clinical assessment

Obtain timeline, prior episodes, psychiatric hospitalisations, suicide attempts, peripartum status, and contextual stressors. Ask directly about hopelessness, burdensomeness, and access to lethal means—plain language reduces iatrogenic risk. Review meds for pro-depressant culprits (certain beta-blockers, high-dose steroids, some anti-seizure drugs, interferon) alongside protective partial agonists already prescribed.

Laboratory investigations

• Targeted metabolic panels when medical mimic suspected: thyroid testing per local algorithms for hypothyroidism, B12/folate when malnutrition or neuropsychiatric signs, pregnancy testing when reproductive status unknown.
• Liver function tests when alcohol misuse or hepatotoxic medications feature; repeat per policy after antidepressant initiation in high-risk groups.
• Urine drug screening when intoxication, diversion risk, or occupational safety warrants objective data—consent and incidental-findings policy per institution.

Imaging

Neuroimaging is not routine; obtain when focal deficits, late-life first presentation with cognitive decline, or other red flags demand structural exclusion per neurology.

Diagnostic criteria / tools

DSM-5-TR symptom clusters remain the lingua franca; integrate PHQ-9/GAD-7 or service-specific batteries to meet measurement-based care expectations outlined across APA patient-facing primers and NHS symptom listings.

↔On a small screen, swipe or scroll sideways to see the full table.

Treatment ladders mirror NICE NG222 and WHO guidance: psychoeducation and structured psychological therapy for milder episodes; combine pharmacotherapy when moderate-to-severe, psychotic features appear, or prior psychotherapy response was inadequate. Psychotic depression or catatonia belongs in specialist / inpatient pathways—antidepressant monotherapy alone is insufficient.

First-line pharmacologic context (prescriber-led)

• SSRIs such as sertraline, escitalopram, or fluoxetine occupy largest tolerability sweet spots for many adults—document baseline sexual function, bleeding risk on anticoagulants, and CYP interactions.
• SNRIs (for example venlafaxine) may help comorbid pain states; monitor blood pressure during titration.
• Mirtazapine can address insomnia and low appetite but contributes sedation and weight gain—useful when those trade-offs match patient goals.
• Bupropion carries less sexual dysfunction burden yet lowers seizure threshold—avoid in eating-disorder populations prone to electrolyte shifts per local policy.

Second-line / specialist options

• Augmentation strategies (lithium, atypical antipsychotics, thyroid augmentation) remain prescriber-managed with metabolic monitoring.
• Treatment-resistant pathways may offer ketamine-class interventions, ECT, or TMS per centre capability and NICE further-line clauses.

Special populations

• Youth: suicidal ideation monitoring intensifies after antidepressant initiation—family safety planning is non-optional.
• Pregnancy / lactation: balance maternal severity against neonatal adaptation signals; involve perinatal psychiatry early.
• Older adults: lower starting doses, orthostasis checks, hyponatraemia surveillance, and falls risk mitigations.

• Screening cadence: USPSTF recommends depression screening in adults when staff-assisted supports exist—document positive screens and close the loop on referrals.
• Follow-up windows: contact within 1–2 weeks of starting or raising antidepressants to review activation, GI tolerance, blood pressure (SNRIs), and emergent suicidality—sooner if high risk.
• Response assessment: meaningful change often requires ≥4–6 weeks at therapeutic dose; partial response triggers augmentation conversations, not silent continuation indefinitely.
• Treatment failure criteria: worsening function, mounting passive death wishes, or intolerance prompting abrupt cessation—latter needs pharmacist input to avoid discontinuation syndromes.
• Referral thresholds: psychiatry for psychosis, bipolar concern, treatment resistance, peripartum emergencies; addiction services when pain and substance use intertwine.

Bedside monitoring checklist

• Vitals including orthostatics when starting sedating or serotonergic combinations in frail adults.
• Weight, glucose, and lipids when metabolic-liability augmenters are added.
• Sodium if older, volume depleted, or on diuretics while SSRIs/SNRIs active.
• Suicide-specific language at each structured touchpoint—means reduction counselling when acute.

• Completed suicide or serious self-harm—emphasises documentation of every escalation decision.
• Functional loss: job exit, custody stress, relationship fracture—social determinants compound relapse.
• Untreated cardiovascular risk clustering when depression drives inactivity, smoking return, or treatment non-adherence.
• Chronicity and cognitive complaints that resemble prodromal neurodegeneration—longitudinal testing clarifies.

Clinically meaningful prevention blends indicated screening, early psychotherapy access, maternal mental-health programmes, workplace psychological safety, and chronic disease management—for example integrating mood screens into diabetes clinics because bidirectional harm is well described (CDC diabetes mental-health page). School-based resilience training and parenting interventions referenced by WHO also reduce incidence in resource-appropriate systems.

Half or more of treated individuals achieve meaningful improvement within 8–12 weeks when therapy, dosing, and adherence align—still, recurrence risk rises with each prior episode, so continuation and maintenance phases matter. Normalize setback conversations: relapse is a signal to adjust intensity, not proof that biological treatments “failed.”

Communication

Use normalising statements (“many people with diabetes carry this emotional load”) to reduce stigma while preserving acute risk language when needed. Offer interpreter or deaf relay services before attributing flat affect to “uncooperativeness.”

Medication safety

Medication administration rounds should confirm patients understand whether to take new antidepressants morning or night, and whether PRN sedatives stack dangerously with opioids or alcohol—reconcile OTC serotonergic cough/cold products.

Documentation

Record verbatim suicidal answers (within clinical note standards), protective factors, means access, and calls placed to crisis lines—legal and continuity protections for the whole team.

Where available, involve crisis lines or emergency psychiatric services aligned with local protocol (for example 988 in the United States).

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of major depressive disorder (DSM-5), structured stepped-care therapy (psychoeducation / talking therapy / SSRI / SNRI / atypicals), suicide-risk assessment and the suicidality / serotonin-syndrome / withdrawal red flags.